Only the HBsAg II assay from Siemens Healthineers offers a “hot zone” and SMART algorithm for greater lab efficiency
The HBsAg II assay available on the Atellica® IM Analyzer and ADVIA Centaur® Immunoassay Systems is designed with patented acridinium ester (AE) technology, allowing for enhanced precision and sensitivity. Incorporating the zwitterionic AE molecule into the assay format results in greater sensitivity and improved detection of HBsAg mutants. A total of five monoclonal antibodies are used in the HBsAgII assay design, greatly improving the assay’s sensitivity and specificity.
Reduce test volumes using the hot zone. Samples in the hot zone (initial results ≥50 Index Units) may be reported as reactive. Only samples with initial values between 1 and <50 Index Units require further testing.
Improve lab efficiency with the SMART algorithm which automatically repeats testing on samples that require further analysis.
Achieve testing accuracy with the use of disposable sample tips which are intended to eliminate sample cross-contamination.
The CDC and European guidelines recommend the use of a fourth-generation HIV screening test for maximum sensitivity and specificity
The CHIV assay available on the Atellica® IM Analyzer and ADVIA Centaur® Immunoassay Systems is a fourth-generation HIV assay offering both excellent sensitivity and specificity. It was designed with patented AE technology to meet current laboratory requirements and future needs for accurate HIV diagnostic testing.
Gain earlier detection capability using a fully automated qualitative combo HIV assay that simultaneously detects the presence of HIV-1 p24 antigen and antibodies to HIV-1 (including group O) and HIV-2 in serum and plasma
Eliminate sample carryover and associated potential for false-positive results with use of disposable sample tips and a one-way workflow
With syphilis rates on the rise, a reverse screening algorithm offers high clinical value
The CDC provides a suggested algorithm for labs wishing to adopt a reverse screening approach for syphilis testing. Reverse screening uses a treponemal test as the initial assay and reactive results are confirmed using nontreponemal methods.1,2 Adoption of a reverse algorithm can improve both clinical detection and workflow if using a sensitive, automated treponemal test.3,4
Siemens Healthineers offers a sensitive treponemal Syphilis assay on both the Atellica® IM Analyzer and ADVIA Centaur® systems that can be incorporated into the Reverse Sequence Screening algorithm.
Achieve higher sensitivity in primary and late-latent disease stages by using the CDC-recommended algorithm for Reverse Sequence Syphilis Screening.2
Receive results quickly with a treponemal antibody test that has good precision and good agreement with a comparative automated syphilis assay.
Detect true positives with good sensitivity and reduce false positives with good specificity.
Consolidate syphilis testing with other high-volume ID, TORCH, and routine assays on one system to improve lab productivity.
Siemens Healthineers provides TORCH and special infectious-disease assays for improved prenatal and specialty care.
Perinatal infections account for 2–3% of all congenital anomalies. TORCH infections, which include Toxoplasmosis, Rubella, Cytomegalovirus (CMV), and Herpes simplex virus (HSV), are some of the most common infections associated with congenital anomalies.*
Delivers fast results so clinicians can counsel their patients on preventing infection, address fetal outcomes if infected, and offer optimal care.
Reduces hands-on labor and improves workflow efficiency and turnaround time with fully automated tests.
Increases lab efficiency by consolidating a broad menu of infectious disease assays on one platform.
Sexually transmitted disease surveillance, 2016 [online]. Atlanta: Centers for Disease Control and Prevention, 2017. Available at: www.cdc.gov/std/stats. Accessed April 13, 2018.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for syphilis infection in nonpregnant adults and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(21):2321−2327; doi: 10.1001/jama.2016.5824.
Ratman S. Can J Infec Dis Med Microbiol. 2005 Jan/Feb;16:(1):45-51.
Larsen SA. Clin Microbiol Rev.1995 Jan;8(1):1-21.
*Stegmann BJ, Carey JC. TORCH infections. Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes infections. Curr Womens Health Rep.2002 Aug;2(4):253-8. PMID: 12150751.
The products/features mentioned here are not commercially available in all countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens Healthineers representative for additional information.